Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Lilly files additional lawsuits over US sales of counterfeit Mounjaro
06:33am, Thursday, 20'th Jun 2024
U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in it
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
02:00pm, Wednesday, 19'th Jun 2024
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
07:15am, Wednesday, 19'th Jun 2024
The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that pos
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
04:36am, Wednesday, 19'th Jun 2024
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.
3 Strong Buy Stocks for a Sizzling Summer Rally
07:15am, Tuesday, 18'th Jun 2024
After last week's data dump of inflation readings and the Federal Reserve's latest decision to hold interest rates steady, investors can take a deep breath before the next earnings season kicks off in
Broadcom Is on Track to Edge Past Eli Lilly's Market Value. AI Is Helping It Do So.
12:32pm, Monday, 17'th Jun 2024
Over its current seven-day streak in the green, Broadcom has snapped up market value that is around the equivalent to McDonald's.
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
09:00am, Monday, 17'th Jun 2024
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp u
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
12:05pm, Sunday, 16'th Jun 2024
Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
02:05pm, Saturday, 15'th Jun 2024
Eli Lilly is developing Mounjaro (tirzepatide) for treating non-alcoholic steatohepatitis. The drugmaker reported positive phase 2 results along those lines earlier this year.
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
07:15am, Saturday, 15'th Jun 2024
Eli Lilly's potential Alzheimer's treatment looks closer than ever to approval. It could be a nice addition to the pharmaceutical giant's already-deep portfolio.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
06:50am, Saturday, 15'th Jun 2024
Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
Exit Alert: 3 Stocks to Offload Before the Downturn
06:12am, Saturday, 15'th Jun 2024
Understanding when to sell a particular stock might be as important in investing as when to acquire it. Here, the focus is on identifying stocks to sell during market downturns, as it is crucial to mi
GLP-1 weight-loss drugs: Analyst discusses what investors should know
02:28pm, Friday, 14'th Jun 2024
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter join
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
01:27pm, Friday, 14'th Jun 2024
The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
12:25pm, Friday, 14'th Jun 2024
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
